Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07206407 · ClinicalTrials.gov registry record · NA

Clinical Trial on Rapid Immune Modulating Effects

A NA study of Immune Surveillance, sponsored by Natural Immune Systems.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT07206407: Recruiting NA study of Immune Surveillance, sponsored by Natural Immune Systems.

NCT07206407 is a NA study of Immune Surveillance that is actively recruiting participants, run by Natural Immune Systems. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07206407, a NA study of Immune Surveillance, is actively recruiting participants, sponsored by Natural Immune Systems.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The goal for this clinical trial is to document rapid effects of a nutritional blend on immune cells. A double-blind, placebo-controlled, cross-over study design will be used.

Primary Outcome

Observation of changes in immune cell trafficking, i.e., the changes in immune cell numbers in the peripheral blood following administration. Data is collected as 'cell numbers per uL whole blood' for the following immune cell types: * Monocytes * NK cells * NKT cells * T cells * non-NK nonT cells

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Nutraceutical blend

Study Locations (1)

Oregon

  • NIS Labs - Klamath Falls

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-09-28
Est. Completion 2026-03-01
Phase NA
Natural Immune Systems

17 total trials

What NCT07206407 shows while recruiting

NCT07206407 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Immune Surveillance appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07206407 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT07206407 about?

NCT07206407 is a clinical study titled "Clinical Trial on Rapid Immune Modulating Effects". The goal for this clinical trial is to document rapid effects of a nutritional blend on immune cells. A double-blind, placebo-controlled, cross-over study design will be used.

What is the current status of trial NCT07206407?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-09-28. Estimated completion is 2026-03-01.

What conditions does trial NCT07206407 study?

This clinical trial studies the following conditions: Immune Surveillance.

What interventions are being tested in trial NCT07206407?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Nutraceutical blend (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07206407?

This trial is sponsored by Natural Immune Systems, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07206407 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Immune Surveillance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07206407's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07206407, the US trial registry maintained by the National Library of Medicine. NCT07206407 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.